Clinical Trials
11 trialsNCT07604233 2026-06-01
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT06429449 2026-01-15
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado, Denver
Phase 1 Recruiting
NCT06501196 2025-09-24
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Phase 1 Recruiting
NCT06643962 2024-11-12
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
Affiliated Hospital of Nantong University
Phase NA Recruiting
NCT03176277 2024-07-15
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT02203773 2023-05-16
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 1 Terminated
NCT04748848 2023-03-02
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Celgene
Phase 1 Terminated
NCT02287233 2022-08-29
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
AbbVie
Phase 1/2 Completed
NCT01994837 2018-06-06
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 2 Completed